MK181, identified by its CAS number 314297-32-0, is a chemical compound that belongs to the class of small molecules. It is primarily recognized for its role as a selective modulator of certain biological pathways, particularly in the context of research related to metabolic disorders and potential therapeutic applications. MK181 exhibits specific interactions with receptors or enzymes, which may influence various physiological processes. The compound's structure typically includes functional groups that contribute to its biological activity and solubility properties. As with many investigational compounds, detailed pharmacokinetic and pharmacodynamic profiles are essential for understanding its efficacy and safety in potential therapeutic contexts. Research on MK181 may involve in vitro and in vivo studies to elucidate its mechanism of action, optimal dosing, and potential side effects. Overall, MK181 represents a promising area of study within medicinal chemistry, with implications for drug development in treating specific health conditions.

MK181 is an AKR1B10 inhibitor. MK181 can bind into the external loop A subpocket. AKR1B10 has evolved as a tumor marker and promising antineoplastic target. It shares high structural similarity with the diabetes target enzyme aldose reductase (AR).

MK181

314297-32-0: MK181, identified by its CAS number 314297-32-0, is a chemical compound that belongs to the class of small molecules. It is primarily recognized for its role as a selective modulator of certain biological pathways, particularly in the context of research related to metabolic disorders and potential therapeutic applications. MK181 exhibits specific interactions with receptors or enzymes, which may influence various physiological processes. The compound's structure typically includes functional groups that contribute to its biological activity and solubility properties. As with many investigational compounds, detailed pharmacokinetic and pharmacodynamic profiles are essential for understanding its efficacy and safety in potential therapeutic contexts. Research on MK181 may involve in vitro and in vivo studies to elucidate its mechanism of action, optimal dosing, and potential side effects. Overall, MK181 represents a promising area of study within medicinal chemistry, with implications for drug development in treating specific health conditions.

<p>MK181 is an inhibitor of AKR1B10, a tumor marker and promising antineoplastic target.</p>

CAS 314297-32-0

MK181

MK181

Ref: TM-T28054